Doravirine associated with greater LDL cholesterol reduction in people with HIV switching antiretroviral regimens
Academic Article
Publication Date:
2025
Short description:
Doravirine associated with greater LDL cholesterol reduction in people with HIV switching antiretroviral regimens / Bellomo, M., Gianotti, N., Hasson, H., Canetti, D., Nozza, S., Guffanti, M., Messina, E., Spagnuolo, V., Lolatto, R., Diotallevi, S., Castagna, A., Galli, L., Muccini, C.. - In: AIDS. - ISSN 0269-9370. - 39:4(2025), pp. 477-479. [10.1097/QAD.0000000000004072]
abstract:
In this observational cohort study, the objective was to compare low-density lipoprotein (LDL) cholesterol dynamics in people with HIV (PWH) who switched to a regimen containing doravirine (DOR), rilpivirine, dolutegravir, or bictegravir and were naïve to the studied drugs.Generalized additive mixed models were used to examine LDL cholesterol dynamics.LDL cholesterol was measured in 2381 PWH: during the first two years, DOR had the greatest lowering effect and showed the most favorable lipid outcome.
Iris type:
1.1 Articolo in rivista
List of contributors:
Bellomo, M.; Gianotti, N.; Hasson, H.; Canetti, D.; Nozza, S.; Guffanti, M.; Messina, E.; Spagnuolo, V.; Lolatto, R.; Diotallevi, S.; Castagna, A.; Galli, L.; Muccini, C.
Published in: